Pharma BD Deal Intelligence
Mallinckrodt's $1.2B Sucampo acquisition wrote itself off within a year—full goodwill impairment in FY2018 after the Niemann-Pick Type C candidate VTS-270 failed Phase 3 that November. Amitiza later hit generic competition in 2021, and Mallinckrodt filed for Chapter 11 bankruptcy in 2020 and again in 2023.
A $1.2B bet that wrote itself off within a year — goodwill fully impaired in FY2018, the rare-disease pipeline asset failed Phase 3, and the buyer went bankrupt twice.
Full analysis, sources & comparables →Mallinckrodt's $1.2B Sucampo bet is less about Amitiza's mature CIC franchise and more about two Phase 3 rare-disease shots-on-goal—VTS-270 in NPC and…
The acquisition brings near-term net sales and earnings accretion through Amitiza and bolsters our pipeline in rare diseases with VTS-270 and…
VTS-270 missed its Phase 2b/3 primary endpoint in Niemann-Pick Type C, with neither arm progressing as expected—a confusing readout that called the program's…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Mallinckrodt agreed to acquire Sucampo Pharmaceuticals via tender offer at $18.00/share in cash, total transaction value approximately $1.2B. The deal added Sucampo's lead commercial product Amitiza (chronic constipation) plus two Phase 3 rare disease assets: CPP-1X/sulindac for familial adenomatous polyposis and VTS-270 for Niemann-Pick Type C. Closed Q1 2018.
A $1.2B bet that wrote itself off within a year — goodwill fully impaired in FY2018, the rare-disease pipeline asset failed Phase 3, and the buyer went bankrupt twice.
Assessment window: 5yr post-close.
$4.6B Global CIC market 2023
Chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) are common functional GI disorders affecting ~16% of US adults, characterized by infrequent, difficult bowel movements without identifiable secondary cause. They impose significant quality-of-life and healthcare-utilization burden. Branded prescription options compete against OTC laxatives and have faced generic erosion since lubiprostone went off-patent in 2018-2020.
Amitiza (lubiprostone, chloride channel-2 activator) competed in a crowded prescription CIC/IBS-C category dominated by Allergan/Ironwood's Linzess (linaclotide, GC-C agonist, market leader by revenue), Synergy/Salix's Trulance (plecanatide, also GC-C), and Shire/Takeda's Motegrity (prucalopride, 5-HT4 agonist; FDA-approved December 2018). At the time of the Mallinckrodt-Sucampo deal, Amitiza generated ~$456M global sales (Wall Street consensus ~$261M for 2018) and held ~15% of the US prescription constipation market. Generic lubiprostone authorized generics began entering 2018, accelerating erosion. Mallinckrodt's strategic rationale extended beyond Amitiza to two Phase 3 rare-disease assets: VTS-270 (adrabetadex/HPβCD) for Niemann-Pick Type C and CPP-1X/sulindac for familial adenomatous polyposis (FAP). Both later failed: VTS-270 missed its Phase 2b/3 primary endpoint in late 2018 and was discontinued in 2021, while Mallinckrodt entered Chapter 11 bankruptcy twice (2020, 2023). The deal exemplified rare-disease pivot ambitions undone by clinical and capital-structure failure. See https://www.fiercepharma.com/pharma/mallinckrodt-inks-1-2b-sucampo-buy-ending-rough-2017-a-high-note
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Mallinckrodt plc / Sucampo Pharmaceuticals, Inc. (this deal) | 2017 | $1.2B | 19 |
| Mallinckrodt plc / Cadence Pharmaceuticals, Inc. | 2014 | $1.4B | 50 |
| Mallinckrodt plc / Therakos, Inc. | 2015 | $1.3B | 48 |
| Mallinckrodt plc / Ikaria, Inc. | 2015 | $2.3B | 37 |
| Mallinckrodt plc / Questcor Pharmaceuticals, Inc. | 2014 | $5.6B | 18 |
| Mallinckrodt plc / InfaCare Pharmaceutical Corporation | 2017 | $425M | 12 |
| UCB SA / Celltech Group plc | 2004 | $2.7B | 92 |
← Browse all deals · How we score deals
More: 2017 deals · Mallinckrodt plc deals · Gastroenterology deals